-
Triiodothyronine T3: Reliable Cell Assays
2026-08-26
Learn how Triiodothyronine (SKU C6407) can be incorporated into controlled cell viability, proliferation, and metabolic experiments. This scenario-based guide covers formulation, vehicle controls, dose-response design, interpretation, and supplier-selection criteria using product data and recent thermogenesis research.
-
Hoechst 33342 for Fibroblast Senescence Assays
2026-08-26
Build reliable live-cell and fixed-cell nuclear readouts for fibroblast aging, mitochondrial quality, and drug-response studies with Hoechst 33342. This workflow emphasizes dilution control, matched imaging settings, and flow-cytometry validation rather than treating nuclear fluorescence as a standalone senescence endpoint.
-
NSC-23766: A Practical Framework for Rac1 Assays
2026-08-25
NSC-23766 is a Rac GTPase inhibitor best understood through integrated target-engagement, phenotype, and mechanism assays. This guide translates evidence from breast cancer, endothelial, and apoptosis models into a rigorous strategy for interpreting Rac1 biology without overclaiming specificity.
-
Bacitracin (B1670): Practical Research Workflow
2026-08-25
Bacitracin (B1670) is a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis disruption. This guide covers solvent selection, stock preparation, QC, and troubleshooting; the material is for scientific research only and should not be used for diagnostic or medical purposes.
-
MDV3100 (Enzalutamide) Research Workflows
2026-08-24
MDV3100 (Enzalutamide) enables phenotype-stratified studies of androgen receptor signaling, apoptosis, and treatment resistance rather than relying on viability data alone. This guide connects practical cell and xenograft workflows with AR-localization controls inspired by a key CRPC heterogeneity study.
-
Reactive Oxygen Species Assay Kit: From Signal to Mechanism
2026-08-24
Learn how the Reactive Oxygen Species Assay Kit converts DCFH-DA fluorescence into interpretable cellular redox data. This guide connects assay design with Nrf2 and EGFR/PI3K/AKT research while clarifying what ROS fluorescence can—and cannot—prove.
-
Streptavidin-Cy3 for NPC Metastasis Assays
2026-08-23
Streptavidin-Cy3 converts biotinylated probes and antibodies into a bright, spatially resolved Cy3 signal for studying carcinogen-associated nasopharyngeal carcinoma metastasis. This guide connects the NPM1/c-Myc/NDRG1 mechanism to practical ISH, IHC, immunofluorescence, and flow cytometry workflows, with starting parameters and troubleshooting strategies.
-
Wogonin, LSD1-p65 Signaling, and Osteoarthritis
2026-08-22
A 2025 Phytomedicine study identifies the LSD1-p65 axis as a mechanistic link between wogonin treatment, macrophage polarization, inflammatory signaling, and osteoarthritis progression. Using DMM mice, macrophage perturbation, transcriptomics, and joint-cell models, the work suggests that regulating macrophage–chondrocyte–osteoblast communication may be important for controlling both cartilage and subchondral bone pathology.
-
S-Adenosylhomocysteine in Neuronal Assays
2026-08-22
Use S-Adenosylhomocysteine to test whether altered methylation potential contributes to radiation-associated neuronal differentiation, rather than treating neurite outgrowth as a purely morphological endpoint. This workflow pairs SAH-driven SAM/SAH ratio modulation with pathway-resolved measurements in C17.2 cells and primary neural stem cells.
-
Intravesical p21 mRNA–LNP Therapy for Bladder Cancer
2026-08-21
The reference study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its data support tumor-suppressor replacement as a transient, bladder-focused strategy that can restore nuclear p21, restrain tumor growth, and limit systemic exposure in an orthotopic mouse model.
-
Fulvestrant (ICI 182,780) Research Workflows
2026-08-20
Fulvestrant (ICI 182,780) provides a practical way to remove ERα signaling while tracking receptor loss, MDM2 protein degradation, apoptosis, and chemotherapy response. This guide connects breast cancer assays with a mechanistic immune-cell study to improve controls, workflow design, and interpretation without overstating cross-model evidence.
-
i-Motif ASO Prodrugs for MYCN-Targeted Therapy
2026-08-20
Zhang and colleagues developed pH-responsive hairpin antisense oligonucleotide prodrugs that use an i-motif switch to control structural stability and acid-triggered release. In MYCN-amplified SK-BE(2) cells, selected R-series constructs, especially R3-5 and R5-5, reduced MYCN expression and promoted apoptosis, providing a structure–activity framework for tumor-microenvironment-responsive nucleic acid therapeutics.
-
MDV3100 (Enzalutamide) Research Workflows
2026-08-19
MDV3100 (Enzalutamide) enables pathway-first studies of androgen receptor blockade, apoptosis, resistance, and therapy-induced senescence in prostate cancer models. This guide translates its mechanism into practical assay workflows, dose planning, reversibility tests, and troubleshooting strategies for castration-resistant prostate cancer research.
-
Danazol C3644: Reliable Assay Design
2026-08-19
Learn how Danazol, SKU C3644, can improve the interpretability of cell viability, proliferation, and endocrine assays through controlled solvent handling, mechanistic controls, and batch-aware selection. This scenario-driven guide connects steroidogenesis data with practical laboratory decisions.
-
Danazol as a Puberty-Modeling Probe
2026-08-18
Danazol offers a mechanistically rich way to study steroidogenesis, hypothalamic–pituitary–gonadal signaling, and endocrine perturbation. This article interprets the danazol-induced precocious puberty model as an assay-design problem, connecting molecular controls, readout selection, and translational limitations.